Spyre Therapeutics said it is deprioritizing its rheumatoid arthritis anti-TL1A antibody program after modest Phase 2 data for its SPY072 candidate. The company indicated the monotherapy results did not meet internal thresholds for success, prompting a shift away from the RA indication. While the announcement does not describe new data beyond the reported Phase 2 outcome, the decision reflects a common mid-stage reality check for immune-modulatory antibodies: target engagement must translate into clinically meaningful endpoints. For investors and collaborators, the key implication is resource reallocation toward programs with clearer probability of Phase 3 viability, potentially accelerating updates on next readouts in other inflammatory indications.